NCT01340833View on ClinicalTrials.gov

Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 8, 2011

Primary Completion Date

September 12, 2011

Study Completion Date

September 12, 2011

Conditions
Cancer
Interventions
DRUG

GSK2118436

Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) \[14C\]GSK2118436, starting 1.75 hours after the oral dose

Trial Locations (1)

98418

GSK Investigational Site, Tacoma

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01340833 - Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors | Biotech Hunter | Biotech Hunter